GlobeImmune, Inc : GlobeImmune Initiates Phase 1a Clinical Trial of GI-13020 in Healthy Volunteers

 GlobeImmune, Inc : GlobeImmune Initiates Phase 1a Clinical Trial of GI-13020
                            in Healthy Volunteers

LOUISVILLE, Colo., Jan. 28, 2013 - GlobeImmune, Inc., today announced the
initiation of a Phase 1a clinical trial to investigate the safety and
immunogenicity of GI-13020 in healthy volunteers. The GI-13020 Tarmogen^®,
which GlobeImmune is developing in collaboration with Gilead Sciences, Inc.,
consists of whole, heat-killed, recombinant S. cerevisiae yeast genetically
modified to express hepatitis B (HBV) antigens. This study is being conducted
under an Investigational New Drug application (IND) that was filed with the
U.S. Food and Drug Administration in December 2012. As a result of
successfully filing the IND, GlobeImmune received a milestone payment from
Gilead.

The GI-13020-01 Phase 1a clinical trial is a randomized, open-label, dose
escalation trial assessing the safety, tolerability and immunogenicity of
various doses of GI-13020 in healthy adults. This study is designed to enroll
48 evaluable subjects at a single U.S. center.

"While approved anti-viral drugs have been shown to effectively suppress
replication of the hepatitis B virus, they rarely result in cures and must be
taken indefinitely," said David Apelian, M.D., Ph.D., Chief Medical Officer at
GlobeImmune. "GI-13020 is designed to activate an antigen-specific immune
response against HBV, and our development strategy will be to combine GI-13020
with direct-acting antiviral medicines to determine if the combination can
increase rates of surface antigen seroconversion, thereby leading to a cure
for infected patients."

HBV infection is the most common form of chronic viral hepatitis in the
world. Approximately 350 million people worldwide are chronic carriers of
HBV, resulting in more than 620,000 deaths annually from liver-related
diseases. In the United States, chronic HBV infection affects up to 1.4
million people. Current treatment for HBV includes once-daily oral antiviral
therapy medicines to suppress virus replication. These antiviral products have
been effective in controlling the disease but generally do not result in a
long-term cure, thus requiring chronic suppressive therapy.

About GlobeImmune
GlobeImmune is a biopharmaceutical company focused on developing products for
the treatment of cancer and infectious diseases based on its proprietary
Tarmogen platform. Tarmogens activate the immune system by stimulating
cellular immunity, known as T cell immunity, in contrast to traditional
vaccines that predominately stimulate antibody production. To date, Tarmogen
product candidates have been generally well tolerated in clinical trials for
multiple disease indications and are efficient to manufacture. In May 2009,
the company entered into a collaboration agreement with Celgene Corporation
focused on the discovery, development and commercialization of product
candidates for the treatment of cancer. In October 2011, the company entered
into a worldwide, strategic collaboration with Gilead Sciences, Inc., to
develop Tarmogens for the treatment of chronic hepatitis B infection. For
additional information, please visit the company's website at
www.globeimmune.com.

                                     ###

Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the
potential for GI-13020 to target HBV and potentially cure an infection, the
Company's ability to successfully complete clinical trials, timing and
eventual prospects for approval to market any of the Company's products and
the prospects for the Company's collaborations. Such statements are based on
management's current expectations and involve risks and uncertainties. Actual
results and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without
limitation, the risks and uncertainties associated with: the Company's
financial resources and whether they will be sufficient to meet the Company's
business objectives and operational requirements; results of earlier studies
and trials may not be predictive of future clinical trial results, the
protection and market exclusivity provided by the Company's intellectual
property; risks related to the drug discovery and the regulatory approval
process; and, the impact of competitive products and technological changes.
The Company disclaims any intent or obligation to update these forward-looking
statements.

GlobeImmune Contact:
David Apelian, M.D., Ph.D., M.B.A.
Chief Medical Officer
T: 303-625-2820
information@globeimmune.com

GlobeImmune Media Contacts:
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251
lena.evans@russopartnersllc.com
tony.russo@russopartnersllc.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: GlobeImmune, Inc via Thomson Reuters ONE
HUG#1673448